AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11772156 — intervention group
Group type: COMPARATOR
Intervention: Hydrocolloid dressing (Duoderm)
Number of subjects: 24
Study 9988985 — intervention group
Group type: EXPERIMENTAL
Intervention: Schizophrenic patients with a history of childhood ADHD
Number of subjects: 77
Study 9988985 — intervention group
Group type: COMPARATOR
Intervention: Control group (schizophrenia only)
Number of subjects: 77
Study 7942234 — intervention group
Group type: EXPERIMENTAL
Intervention: Orange juice (1 litre daily)
Number of subjects: 0
Study 7942234 — intervention group
Group type: COMPARATOR
Intervention: Diet and increased fluid intake
Number of subjects: 0
Study 3281997 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen, 1 mg in the evening during 1 week
Number of subjects: 19
Study 3281997 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen, 1 mg, twice daily, during 3 weeks
Number of subjects: 19
Study 3281997 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 3281997 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol, 300 micrograms, four times a day
Number of subjects: 19
Study 29112594 — intervention group
Group type: COMPARATOR
Intervention: Former EPT users
Number of subjects: 13902
Study 29112594 — intervention group
Group type: COMPARATOR
Intervention: Former placebo users (for EPT)
Number of subjects: 13902
Study 29112594 — intervention group
Group type: COMPARATOR
Intervention: Former ET users
Number of subjects: 13902
Study 29112594 — intervention group
Group type: COMPARATOR
Intervention: Former placebo users (for ET)
Number of subjects: 13902
Study 27855265 — intervention group
Group type: EXPERIMENTAL
Intervention: AVG intervention (Xbox 360), played twice per week for 60 minutes over 12 weeks
Number of subjects: 80
Study 27855265 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 80
Study 24839883 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX) at optimized doses of 30, 50, or 70 mg per day
Number of subjects: 276
Study 24839883 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 276
Study 23331528 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray (MFNS) 100 μg once or twice daily
Number of subjects: 127
Study 23331528 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray (MFNS) 200 μg once or twice daily
Number of subjects: 127
Study 23331528 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 127
Study 23331528 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray (MFNS)
Number of subjects: 127
Study 20118486 — intervention group
Group type: EXPERIMENTAL
Intervention: eGFRCG (Cockcroft-Gault equation)
Number of subjects: 134
Study 20118486 — intervention group
Group type: EXPERIMENTAL
Intervention: eGFRMC (Mayo Clinic equation)
Number of subjects: 134
Study 20118486 — intervention group
Group type: EXPERIMENTAL
Intervention: eGFRCKD-EPI (Chronic Kidney Disease Epidemiology Collaboration equation)
Number of subjects: 134
Study 20118486 — intervention group
Group type: EXPERIMENTAL
Intervention: eGFRMDRD (Modification of Diet in Renal Disease equation)
Number of subjects: 134
Study 20118486 — intervention group
Group type: COMPARATOR
Intervention: Steroid exposure
Number of subjects: 134
Study 18787325 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-compound scalp formulation (calcipotriol 50 microg/g plus betamethasone dipropionate 0.5 mg/g)
Number of subjects: 869
Study 18787325 — intervention group
Group type: COMPARATOR
Intervention: Calcipotriol (50 microg/g)
Number of subjects: 869
Study 16894800 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified transition concept (therapeutic weekend care, bedside teaching, structured information for relatives)
Number of subjects: 70
Study 16894800 — intervention group
Group type: COMPARATOR
Intervention: Standard transition
Number of subjects: 70
Study 12832684 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone 1000 micro g
Number of subjects: 10
Study 12832684 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone 1000 micro g
Number of subjects: 10
Study 12832684 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 10973837 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptifibatide treatment in patients with significant CAD
Number of subjects: 5767
Study 10973837 — intervention group
Group type: COMPARATOR
Intervention: Placebo in patients with significant CAD
Number of subjects: 5767
Study 10973837 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptifibatide treatment in patients with mild CAD
Number of subjects: 5767
Study 10973837 — intervention group
Group type: COMPARATOR
Intervention: Placebo in patients with mild CAD
Number of subjects: 5767
Study 10973837 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptifibatide treatment in patients with no CAD
Number of subjects: 5767
Study 10973837 — intervention group
Group type: COMPARATOR
Intervention: Placebo in patients with no CAD
Number of subjects: 5767
Study 8633745 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma education program for parents
Number of subjects: 3
Study 8633745 — intervention group
Group type: COMPARATOR
Intervention: Number of smokers in the family
Number of subjects: 3
Study 8633745 — intervention group
Group type: COMPARATOR
Intervention: Perceived adverse impact of asthma on the family
Number of subjects: 3
Study 8633745 — intervention group
Group type: COMPARATOR
Intervention: Demographic characteristics, frequency of asthma symptoms, and health care use
Number of subjects: 3
Study 8633745 — intervention group
Group type: COMPARATOR
Intervention: Smoking status of parents
Number of subjects: 3
Study 8267058 — intervention group
Group type: EXPERIMENTAL
Intervention: Dehydroepiandrosterone supplementation
Number of subjects: 11
Study 3099944 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g amoxycillin syrup
Number of subjects: 38
Study 3099944 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 30067591 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy-resistance exercise (10 × 5 back squats at 80% one-repetition maximum)
Number of subjects: 10
Study 30067591 — intervention group
Group type: EXPERIMENTAL
Intervention: Jumping exercise (10 × 5 jump squats)
Number of subjects: 10
Study 30067591 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal sprinting (15 × 30 m)
Number of subjects: 10
Study 26903238 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory processing‐based exercises (40 hours)
Number of subjects: 83
Study 26903238 — intervention group
Group type: COMPARATOR
Intervention: Computer games (CG)
Number of subjects: 83
Study 24373307 — intervention group
Group type: COMPARATOR
Intervention: 8-IM group
Number of subjects: 0
Study 24373307 — intervention group
Group type: COMPARATOR
Intervention: 7-IM, 5-IM, 4-IM groups
Number of subjects: 0
Study 24373307 — intervention group
Group type: COMPARATOR
Intervention: 8-IM, 5-IM, 4-IM groups
Number of subjects: 0
Study 24373307 — intervention group
Group type: COMPARATOR
Intervention: IM group
Number of subjects: 0
Study 24373307 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 dose IM priming schedule
Number of subjects: 0
Study 23770132 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine (2.5 mg · kg(‐1) · day(‐1))
Number of subjects: 131
Study 23770132 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 131
Study 20040914 — intervention group
Group type: EXPERIMENTAL
Intervention: Arbaclofen placarbil (AP)
Number of subjects: 50
Study 20040914 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 18950402 — intervention group
Group type: EXPERIMENTAL
Intervention: Mineral oil pretreated side
Number of subjects: 20
Study 18950402 — intervention group
Group type: COMPARATOR
Intervention: Emollient-free control side
Number of subjects: 20
Study 16319477 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical corticosteroid prednicarbat plus wet‐wrap dressing
Number of subjects: 24
Study 16319477 — intervention group
Group type: COMPARATOR
Intervention: Topical corticosteroid prednicarbat alone
Number of subjects: 24
Study 12834495 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexetidine 0.1% mouthwash
Number of subjects: 134
Study 12834495 — intervention group
Group type: COMPARATOR
Intervention: Chlorhexidine 0.12% mouthwash (positive control)
Number of subjects: 134
Study 12834495 — intervention group
Group type: COMPARATOR
Intervention: 5% hydroalcohol mouthwash (negative control)
Number of subjects: 134
Study 10830159 — intervention group
Group type: EXPERIMENTAL
Intervention: Explanatory therapy
Number of subjects: 20
Study 10830159 — intervention group
Group type: COMPARATOR
Intervention: Waiting list followed by explanatory therapy
Number of subjects: 20
Study 8841149 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroergotamine nasal spray (1 mg)
Number of subjects: 9
Study 8841149 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroergotamine nasal spray (1 to 4 mg)
Number of subjects: 9
Study 8841149 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroergotamine nasal spray (1 mg) with caffeine (1%)
Number of subjects: 9
Study 8841149 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroergotamine nasal spray (1 mg) during vasomotor phenomena
Number of subjects: 9
Study 8841149 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroergotamine nasal spray (1 mg) with fenoxazoline
Number of subjects: 9
Study 8841149 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroergotamine nasal spray (1 mg) during acute viral rhinitis
Number of subjects: 9
Study 8841149 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroergotamine nasal spray
Number of subjects: 9
Study 1370568 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous procaine and low‐molecular‐weight dextran
Number of subjects: 27
Study 1370568 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 6129077 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 11
Study 6129077 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenoxybenzamine
Number of subjects: 11
Study 6129077 — intervention group
Group type: COMPARATOR
Intervention: Prazosin and Phenoxybenzamine (chronic therapy)
Number of subjects: 11
Study 31451249 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 ml apple vinegar per day for 8 weeks
Number of subjects: 70
Study 31451249 — intervention group
Group type: COMPARATOR
Intervention: Control group (no apple vinegar)
Number of subjects: 70
Study 31451249 — intervention group
Group type: COMPARATOR
Intervention: Both groups (apple vinegar and control)
Number of subjects: 70
Study 29512476 — intervention group
Group type: EXPERIMENTAL
Intervention: Wii Fit balance platform
Number of subjects: 40
Study 29512476 — intervention group
Group type: COMPARATOR
Intervention: Standard customised vestibular rehabilitation protocol
Number of subjects: 40
Study 26897443 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous insulin (regular insulin)
Number of subjects: 202
Study 22913726 — intervention group
Group type: EXPERIMENTAL
Intervention: Trevo Retriever(TM)
Number of subjects: 33
Study 22913726 — intervention group
Group type: COMPARATOR
Intervention: Solitaire Stent(TM)
Number of subjects: 33
Study 22310061 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyvinyl acetal sponge nasal packing (Merocel)
Number of subjects: 60
Study 22310061 — intervention group
Group type: COMPARATOR
Intervention: No nasal packing
Number of subjects: 60
Study 20432399 — intervention group
Group type: EXPERIMENTAL
Intervention: sc enoxaparin with protocol-mandated IV enoxaparin bolus (0.3 mg/kg)
Number of subjects: 4687
Study 20432399 — intervention group
Group type: COMPARATOR
Intervention: sc enoxaparin without protocol-mandated IV enoxaparin bolus
Number of subjects: 4687
Study 18077136 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone
Number of subjects: 130
Study 18077136 — intervention group
Group type: COMPARATOR
Intervention: Clozapine
Number of subjects: 130
Study 16027621 — intervention group
Group type: EXPERIMENTAL
Intervention: Fränkel appliance therapy
Number of subjects: 78
Study 16027621 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated Class II malocclusion and normal occlusions)
Number of subjects: 78
Study 12450026 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic autoregulatory index (ARI) tests performed every 12 hours during the first 5 days postinjury and daily during the next 5 days
Number of subjects: 122
Study 12450026 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebral blood flow (CBF) measurements
Number of subjects: 122
Study 12450026 — intervention group
Group type: EXPERIMENTAL
Intervention: Middle cerebral artery blood flow velocity (BFV) measurements
Number of subjects: 122
Study 12450026 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrovascular resistance (CVR) measurements
Number of subjects: 122
Study 12450026 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of BFV on Day 1
Number of subjects: 122
Study 10418839 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with spastic diplegic cerebral palsy under compliant foot support with occluded or sway referenced vision
Number of subjects: 21
Study 10418839 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with spastic diplegic cerebral palsy under fixed foot support
Number of subjects: 21
Study 10418839 — intervention group
Group type: COMPARATOR
Intervention: Matched controls under compliant foot support with occluded or sway referenced vision
Number of subjects: 21
Study 10418839 — intervention group
Group type: COMPARATOR
Intervention: Matched controls under fixed foot support
Number of subjects: 21
Study 7778318 — intervention group
Group type: EXPERIMENTAL
Intervention: Camonagrel (800 mg orally)
Number of subjects: 0
Study 7778318 — intervention group
Group type: EXPERIMENTAL
Intervention: Camonagrel (10 mg/kg i.v.) in cats
Number of subjects: 0
Study 7778318 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (50 mg/kg i.v.) pretreatment
Number of subjects: 0
Study 7778318 — intervention group
Group type: COMPARATOR
Intervention: L-NAME (100 micrograms/kg/min, i.v.) pretreatment
Number of subjects: 0
Study 2404314 — intervention group
Group type: EXPERIMENTAL
Intervention: Color duplex sonography
Number of subjects: 26
Study 2404314 — intervention group
Group type: COMPARATOR
Intervention: Angiography
Number of subjects: 26
Study 30063644 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol 5 mg (single dose)
Number of subjects: 38
Study 30063644 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan 150 mg (single dose)
Number of subjects: 38
Study 30063644 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol (weekly administration)
Number of subjects: 38
Study 30063644 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan (weekly administration)
Number of subjects: 38
Study 29054815 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-brain radiotherapy (WBRT)
Number of subjects: 118
Study 29054815 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous stem-cell transplantation (ASCT)
Number of subjects: 118
Study 29054815 — intervention group
Group type: COMPARATOR
Intervention: Comparison of WBRT and ASCT
Number of subjects: 118
Study 25927718 — intervention group
Group type: EXPERIMENTAL
Intervention: The Virtual Week Training Program - a computerized prospective memory (PM) training program
Number of subjects: 200
Study 25927718 — intervention group
Group type: COMPARATOR
Intervention: non-adaptive computer-based word puzzles (active control)
Number of subjects: 200
Study 23662960 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact Lens Spherical Aberration control
Number of subjects: 96
Study 23662960 — intervention group
Group type: EXPERIMENTAL
Intervention: Vision Training
Number of subjects: 96
Study 23662960 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 96
Study 21601352 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening arm (men with interval cancer)
Number of subjects: 42376
Study 21601352 — intervention group
Group type: COMPARATOR
Intervention: Control arm (men with PCa)
Number of subjects: 42376
Study 18645103 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple-nodal basin drainage
Number of subjects: 2060
Study 18645103 — intervention group
Group type: COMPARATOR
Intervention: Single-nodal basin drainage
Number of subjects: 2060
Study 16445724 — intervention group
Group type: EXPERIMENTAL
Intervention: TTE (transthoracic echocardiography)
Number of subjects: 60
Study 16445724 — intervention group
Group type: COMPARATOR
Intervention: x-ray fluoroscopy
Number of subjects: 60
Study 12952369 — intervention group
Group type: EXPERIMENTAL
Intervention: tibolone 2.5 mg
Number of subjects: 748
Study 12952369 — intervention group
Group type: EXPERIMENTAL
Intervention: 17beta‐estradiol 2 mg plus norethisterone acetate 1 mg (E2/NETA)
Number of subjects: 748
Study 12952369 — intervention group
Group type: EXPERIMENTAL
Intervention: conjugated equine estrogen 0.625 mg (CEE)
Number of subjects: 748
Study 12952369 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE/MPA
Number of subjects: 748
Study 12952369 — intervention group
Group type: EXPERIMENTAL
Intervention: raloxifene HCI 60 mg
Number of subjects: 748
Study 12952369 — intervention group
Group type: EXPERIMENTAL
Intervention: E2/NETA
Number of subjects: 748
Study 12952369 — intervention group
Group type: COMPARATOR
Intervention: non‐users of replacement therapy
Number of subjects: 748
Study 11075556 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 0.5 mg.kg‐1
Number of subjects: 36
Study 11075556 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 1.0 mg.kg‐1
Number of subjects: 36
Study 11075556 — intervention group
Group type: COMPARATOR
Intervention: Lactated Ringer's solution 5 ml (control group)
Number of subjects: 36
Study 9202366 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicorandil
Number of subjects: 0
Study 9202366 — intervention group
Group type: COMPARATOR
Intervention: Nitroglycerin
Number of subjects: 0
Study 9202366 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 0
Study 1440804 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefloquine 15 mg/kg
Number of subjects: 85
Study 1440804 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefloquine 25 mg/kg
Number of subjects: 85
Study 1440804 — intervention group
Group type: COMPARATOR
Intervention: In vitro sensitivity to mefloquine
Number of subjects: 85
Study 1440804 — intervention group
Group type: COMPARATOR
Intervention: In vitro sensitivity to chloroquine
Number of subjects: 85
Study 4041306 — intervention group
Group type: EXPERIMENTAL
Intervention: Procaine
Number of subjects: 10
Study 4041306 — intervention group
Group type: EXPERIMENTAL
Intervention: Amethocaine
Number of subjects: 10
Study 4041306 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepivacaine
Number of subjects: 10
Study 4041306 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinchocaine
Number of subjects: 10
Study 4041306 — intervention group
Group type: EXPERIMENTAL
Intervention: Lignocaine
Number of subjects: 10
Study 4041306 — intervention group
Group type: EXPERIMENTAL
Intervention: Prilocaine
Number of subjects: 10
Study 31083855 — intervention group
Group type: EXPERIMENTAL
Intervention: Tele-nursing follow-up (phone by nurses for 12 weeks, twice a week for the first month and once a week for the following two months)
Number of subjects: 60
Study 31083855 — intervention group
Group type: EXPERIMENTAL
Intervention: Tele-nursing follow-up
Number of subjects: 60
Study 31083855 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual follow-up by a specialist)
Number of subjects: 60
Study 27431234 — intervention group
Group type: EXPERIMENTAL
Intervention: Tribendimidine 25 mg
Number of subjects: 68
Study 27431234 — intervention group
Group type: EXPERIMENTAL
Intervention: Tribendimidine 400 mg
Number of subjects: 68
Study 27431234 — intervention group
Group type: EXPERIMENTAL
Intervention: Tribendimidine (various doses)
Number of subjects: 68
Study 27431234 — intervention group
Group type: EXPERIMENTAL
Intervention: Tribendimidine 200 mg
Number of subjects: 68
Study 27431234 — intervention group
Group type: EXPERIMENTAL
Intervention: Tribendimidine (25 to 200 mg)
Number of subjects: 68
Study 24762684 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-bismuth quadruple therapy for 7 days (esomeprazole 20 mg, amoxicillin 1000 mg, clarithromycin 500 mg, tinidazole 500 mg given twice daily)
Number of subjects: 246
Study 24762684 — intervention group
Group type: COMPARATOR
Intervention: Standard triple therapy for 7 days (esomeprazole 20 mg, amoxicillin 1000 mg, clarithromycin 500 mg given twice daily)
Number of subjects: 246
Study 24762684 — intervention group
Group type: COMPARATOR
Intervention: Standard triple therapy for 10 days (esomeprazole 20 mg, amoxicillin 1000 mg, clarithromycin 500 mg given twice daily)
Number of subjects: 246
Study 24762684 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-bismuth quadruple therapy
Number of subjects: 246
Study 24762684 — intervention group
Group type: COMPARATOR
Intervention: Standard triple therapy for 7 days
Number of subjects: 246
Study 24762684 — intervention group
Group type: COMPARATOR
Intervention: Standard triple therapy for 10 days
Number of subjects: 246
Study 22356304 — intervention group
Group type: EXPERIMENTAL
Intervention: Formalin dab (4%)
Number of subjects: 102
Study 22356304 — intervention group
Group type: COMPARATOR
Intervention: Sucralfate-steroid retention enema
Number of subjects: 102
Study 19778361 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body phototherapy
Number of subjects: 99
Study 19778361 — intervention group
Group type: COMPARATOR
Intervention: Placebo light
Number of subjects: 99
Study 19029264 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimized extracorporeal circulation system (MECC)
Number of subjects: 80
Study 19029264 — intervention group
Group type: COMPARATOR
Intervention: Usual pump (control group)
Number of subjects: 80
Study 16183654 — intervention group
Group type: EXPERIMENTAL
Intervention: Postcards intervention (eight postcards over 12 months) along with standard treatment
Number of subjects: 772
Study 16183654 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment alone
Number of subjects: 772
Study 12190164 — intervention group
Group type: EXPERIMENTAL
Intervention: FDG-PET
Number of subjects: 59
Study 12190164 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydro-MRI
Number of subjects: 59
Study 12190164 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte scintigraphy
Number of subjects: 59
Study 12190164 — intervention group
Group type: COMPARATOR
Intervention: Control (Irritable bowel syndrome and tumor patients)
Number of subjects: 59
Study 10072215 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirofiban followed by randomization to invasive strategy
Number of subjects: 0